Ocrelizumab and serious infections
Great article from Gavin Giannoni on this topic. Applies to Kesimpta and rituximab as well. If you have Substack, you can read for free.
https://open.substack.com/pub/gavingiovannoni/p/serious-infections-on-anti-cd20-therapies?r=2f3ys&utm_medium=ios
Bottom line - there is a 7% risk of serious infe...